posted
Looking to go on news. at .021 right now with an OS of 119,118,519 (edited, I copied the wrong O/S, sorry guys)
Business Editors / Health/Fitness Writers
HOUSTON--(BUSINESS WIRE)--Feb. 7, 2006-- Endovasc Inc. (OTCBB:EVSC, OTC: EVSD), today announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office for its pending patent application entitled "Development of Muscle Mass in a Mammal". The patent covers the use of the Company's non-steroidal supplement technology for muscle cell recruiting and accelerated bodybuilding and strengthens Endovasc's nutraceutical intellectual property portfolio currently incorporated in the Endothil-CR product marketed by Basic Research. "This patent adds a new layer to our Company's broad intellectual property portfolio and demonstrates Endovasc's innovation in the field of nutraceuticals. We are committed to commercializing our pipeline of nutraceutical products. Patent protection such as this is critical for ensuring Endothil-CR's exclusivity in the marketplace," said Diane Dottavio, Ph.D., Endovasc's Chairman and Chief Executive Officer. Endovasc's wholly owned subsidiary, Nutraceutical Development Corporation (NDC), licensed the technology to Basic Research to develop and market a non-steroid supplement which utilizes the Company's muscle mass technology. Endothil-CR is currently available at GNC stores nationwide or on the World Wide Web at www.Endothil.com.
About Endovasc, Inc.
Endovasc, Inc is focused on developing and commercializing drug candidates in the areas of cardiovascular and metabolic medicine. Endovasc is organized as a business development company, operating through the following subsidiaries: Liprostin Inc., which holds the intellectual property for a liposomal based treatment to increase circulation and reduce leg pain in patients suffering from vascular disease; Prostent, Inc., which is developing urinary tract stent coating technology; and Nutraceutical Development Corporation.
This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.
KEYWORD: NORTH AMERICA TEXAS UNITED STATES INDUSTRY KEYWORD: HEALTH CARDIOLOGY FITNESS & NUTRITION RESEARCH & SCIENCE SOURCE: Endovasc Inc.
CONTACT INFORMATION: ZA Consulting Inc. David Zazoff, 212-505-5976
posted
Holy cow, .35 now. Guess I missed the boat on this one. You thnk my .025 order will get filled...? Good luck to all of you who got in
IP: Logged |
posted
too late to buy this? whats ur suggested price to get in at and should i also follow it for an order to sell for today? i dont have time to do research, but i have an instinct after some quick skimming to buy in. how much of a gainfor today and where should i get in
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Frown]](frown.gif)
![[Smile]](smile.gif)
Good luck to all of you who got in
